The adenosine A 1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure

British Journal of Pharmacology

Volumn 151, Issue 7, 2007, Pages 1025-1032

  Kalk, P ^a,b   Eggert, B ^a   Relle, K ^a,b   Godes, M ^a,b   Heiden, S ^a   Sharkovska, Y ^a   Fischer, Y ^c   Ziegler, D ^c   Bielenberg, G W ^c   Hocher, B ^a,c  

^a DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Adenosine receptor; Chronic renal failure; Myocardial fibrosis

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; KETAMINE; SLV 320; UNCLASSIFIED DRUG; XYLAZINE; 1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE A1 RECEPTOR; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLOHEXANE DERIVATIVE; FIBRONECTIN; FUSED HETEROCYCLIC RINGS; ROLIPRAM; SLV320 COMPOUND; XANTHINE DERIVATIVE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BLOOD SAMPLING; CARDIOMYOPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SELECTIVITY; ENZYME ASSAY; GLOMERULUS FILTRATION RATE; HEART MUSCLE FIBROSIS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY FUNCTION; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SHAM FEEDING; SPRAGUE DAWLEY RAT; ANIMAL; CELL LINE; CELL STRAIN U937; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; HEART MUSCLE; HUMAN; METABOLISM; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RADIOASSAY;

ADENOSINE; ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BLOOD PRESSURE; CELL LINE; COLLAGEN TYPE I; COLLAGEN TYPE III; CREATINE KINASE; CYCLOHEXANES; ENDOMYOCARDIAL FIBROSIS; FIBRONECTINS; GLOMERULAR FILTRATION RATE; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; MALE; MOLECULAR STRUCTURE; MYOCARDIUM; NEPHRECTOMY; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A1; ROLIPRAM; U937 CELLS; XANTHINES;

EID: 34547572688     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707319     Document Type: Article

References (33)

1. Amann K, Breitbach M, Ritz E, Mall G (1998a). Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9: 1018-1022.
2. Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Munter K et al. (1998b). Cardiac remodelling in experimental renal failure - an immunohistochemical study. Nephrol Dial Transplant 13: 1958-1966.
3. Arakawa K, Suzuki H, Naitoh M, Matsumoto A, Hayashi K, Matsuda H et al. (1996). Role of adenosine in the renal responses to contrast medium. Kidney Int 49: 1199-1206.
4. Auchampach JA, Jin X, Moore J, Wan TC, Kreckler LM, Ge ZD et al. (2004). Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. J Pharmacol Exp Ther 308: 846-856.
5. Bak M, Thomsen K (2004). Effects of the adenosine A1 receptor inhibitor FK 838 on proximal tubular fluid output in rats. Nephrol Dial Transplant 19: 1077-1082.
6. Basi S, Lewis JB (2006). Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 47: 927-946.
7. Becker BF, Zahler S, Seligmann C, Kupatt C, Habazettl H (1996). [Interaction of adenosine with leukocytes and thrombocytes]. Z Kardiol 85 (Suppl 6): 161-170.
8. Chen Y, Epperson S, Makhsudova L, Ito B, Suarez J, Dillmann W et al. (2004). Functional effects of enhancing or silencing adenosine A2b receptors in cardiac fibroblasts. Am J Physiol Heart Circ Physiol 287: H2478-H2486.
9. Dubey RK, Gillespie DG, Jackson EK (1998). Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A2B receptors. Hypertension 31: 943-948.
10. Dubey RK, Gillespie DG, Zacharia LC, Mi Z, Jackson EK (2001). A(2b) receptors mediate the antimitogenic effects of adenosine in cardiac fibroblasts. Hypertension 37: 716-721.
11. Ely SW, Berne RM (1992). Protective effects of adenosine in myocardial ischemia. Circulation 85: 893-904.
12. Foley RN, Herzog CA, Collins AJ (2003). Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study. Kidney Int 63: 1462-1467.
13. Forman MB, Vitola JV, Velasco CE, Murray JJ, Dubey RK, Jackson EK (2000). Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist: possible role of the neutrophil chemoattractant response. J Pharmacol Exp Ther 292: 929-938.
14. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J (2001). International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552.
15. Funakoshi H, Chan TO, Good JC, Libonati JR, Piuhola J, Chen X et al. (2006). Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac morphology and function. Circulation 114: 2240-2250.
16. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S et al. (2002). BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105: 1348-1353.
17. Gretz N (1995). The development of hypertension in the remnant kidney model after either pole resection or partial infarction of the kidney. J Am Soc Nephrol [Lett] 5: 1839-1840.
18. Gross GJ, Mei DA, Sleph PG, Grover GJ (1997). Adenosine A1 receptor blockade does not abolish the cardioprotective effects of the adenosine triphosphate-sensitive potassium channel opener bimakalim. J Pharmacol Exp Ther 280: 533-540.
19. Guerin AP, Adda H, London GM, Marchais SJ (2004). Cardiovascular disease in renal failure. Minerva Urol Nefrol 56: 279-288.
20. Haffner D, Hocher B, Muller D, Simon K, Konig K, Richter CM et al. (2005). Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 23: 1067-1075.
21. Hocher B, George I, Diekmann F, Zart R, Rebstock J, Schwarz A et al. (2000). ETA receptor blockade induces fibrosis of the clipped kidney in two-kidney-one-clip renovascular hypertensive rats. J Hypertens 18: 1807-1814.
22. Hocher B, George I, Rebstock J, Bauch A, Schwarz A, Neumayer HH et al. (1999). Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension 33: 816-822.
23. Jackson EK, Kost Jr CK, Herzer WA, Smits GJ, Tofovic SP (2001). A(1) receptor blockade induces natriuresis with a favorable renal hemodynamic profile in SHHF/Mcc-fa(cp) rats chronically treated with salt and furosemide. J Pharmacol Exp Ther 299: 978-987.
24. Kalk P, Godes M, Relle K, Rothkegel C, Hucke A, Stasch JP et al. (2006). NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy. Br J Pharmacol 148: 853-859.
25. Kis A, Baxter GF, Yellon DM (2003). Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2. Cardiovasc Drugs Ther 17: 415-425.
26. Linden J (2001). Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 41: 775-787.
27. Nagashima K, Kusaka H, Karasawa A (1995). Protective effects of KW-3902, an adenosine A1-receptor antagonist, against cisplatin-induced acute renal failure in rats. Jpn J Pharmacol 67: 349-357.
28. Raschke P, Becker BF (1995). Adenosine and PAF dependent mechanisms lead to myocardial reperfusion injury by neutrophils after brief ischaemia. Cardiovasc Res 29: 569-576.
29. Ren Y, Garvin JL, Carretero OA (2001). Efferent arteriole tubuloglomerular feedback in the renal nephron. Kidney Int 59: 222-229.
30. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saunders T et al. (2001). Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA 98: 9983-9988.
31. Wilcox CS, Welch WJ, Schreiner GF, Belardinelli L (1999). Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J Am Soc Nephrol 10: 714-720.
32. Xu Z, Downey JM, Cohen MV (2001). Amp 579 reduces contracture and limits infarction in rabbit heart by activating adenosine A2 receptors. J Cardiovasc Pharmacol 38: 474-481.
33. Yamagata T, Kobayashi T, Kusaka H, Karasawa A (1994). Diuretic effects of KW-3902, a novel adenosine A1-receptor antagonist, in anesthetized dogs. Biol Pharm Bull 17: 1599-1603.